Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Oncology Practice

• Publication date

  2017-04-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JOP.2016.019588PMID 28437150PMCID PMC5470648
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle

  2016cited by this paper
• COST OF FEBRILE NEUTROPENIA TREATMENT IN BOSNIA AND HERZEGOVINA

  2016cited by this paper
• Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2015cited by this paper
• Why pediatric patients with cancer visit the emergency department: United States, 2006–2010

  2015cited by this paper
• Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.

  2015cited by this paper
• Costs associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore

  2014cited by this paper
• Preventing infections during cancer treatment: development of an interactive patient education website.

  2014cited by this paper
• History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.

  2014cited by this paper
• Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.

  2014influential reference
• A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia

  2013influential reference
• Hematopoietic stem cell transplantation for chronic lymphocytic leukemia

  2012cited by this paper
• Pediatric Cancer Hospitalizations, 2009

  2012cited by this paper
• CDC launches infection awareness initiative for cancer patients.

  2012cited by this paper
• Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults

  2012cited by this paper
• Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer

  2012cited by this paper
• Costs Associated with Febrile Neutropenia in the US

  2012cited by this paper
• Hepatitis B outbreak associated with a hematology-oncology office practice in New Jersey, 2009.

  2011cited by this paper
• Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study.

  2011cited by this paper
• Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission.

  2011cited by this paper
• Risk of mortality in patients with cancer who experience febrile neutropenia

  2010influential reference
• Evaluation of direct medical costs of hospitalization for febrile neutropenia

  2010cited by this paper
• Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.

  2009influential reference
• Future of cancer incidence in the United States: burdens upon an aging, changing nation.

  2009cited by this paper
• Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

  2009cited by this paper
• Nosocomial infections in patients with cancer.

  2009cited by this paper
• The epidemiology and treatment of infections in cancer patients.

  2008cited by this paper
• Prevalence of Outpatient Cancer Treatment in the United States: Estimates from the Medical Panel Expenditures Survey (MEPS)

  2008cited by this paper
• Ambulatory care for cancer in the United States: results from two national surveys comparing visits to physicians' offices and hospital outpatient departments.

  2007cited by this paper
• Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

  2006cited by this paper
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

  2006cited by this paper
• An Outbreak of Hepatitis C Virus Infections among Outpatients at a Hematology/Oncology Clinic

  2005cited by this paper
• Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

  2005cited by this paper
• Outbreak of catheter-associated Klebsiella oxytoca and Enterobacter cloacae bloodstream infections in an oncology chemotherapy center.

  2005cited by this paper
• Population aging and cancer: a cross-national concern.

  2005cited by this paper
• History forgotten is history relived: nosocomial infection control is also essential in the outpatient setting.

  2005cited by this paper
• Viral hepatitis transmission in ambulatory health care settings.

  2004cited by this paper
• Management of health-care--associated infections in the oncology patient.

  2003cited by this paper
• Risk of Mortality in Patients with End-Stage Renal Disease: The Role of Malnutrition and Possible Therapeutic Implications

  2002cited by this paper
• Infection control and changing health-care delivery systems.

  2001cited by this paper
• Predictive Margins with Survey Data

  1999cited by this paper

• Early Discontinuation of Empiric Antibiotic Therapy in Children with Cancer and Febrile Neutropenia: A Narrative Review

  2026cites this paper
• Evaluation of Direct Medical Costs Associated With High-Risk Febrile Neutropenia Among Cancer Patients in a Tertiary Care Center.

  2026cites this paper
• Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study

  2025cites this paper
• Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study

  2025cites this paper
• Clinical Outcome of Febrile Neutropenia and Associated Factors Among Adult Patients with Cancer Treated at Ethiopian Oncology Centers: A Retrospective Observational Study

  2025cites this paper
• [Management of febrile neutropenia].

  2025cites this paper
• Determining the Cut-Off Value of the MASCC Score to Predict Mortality in Hospitalized Febrile Neutropenic Patients: A Decade-Long Single-Center Retrospective Cohort Study

  2025cites this paper
• Real-World Data to Assess the Proportion of Patients Admitted for Febrile Neutropenia That Could Be Considered at Low Risk: The Experience of the Centre Hospitalier Universitaire de Québec

  2025cites this paper
• Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation

  2025cites this paper
• Evaluation of a Febrile Neutropenia Protocol Implemented at Triage in an Emergency Department

  2025influential citation
• Chemotherapy-induced adipo-lineage cell senescence drives bone loss

  2025cites this paper
• Acute oncology: the care of older patients in the emergency department.

  2025cites this paper
• Step-down management of fever and neutropenia in low-risk pediatric and adolescent-young adult oncology patients is safe and effective: a single center experience

  2025cites this paper
• Novel Wearable-Based Real-Time Temperature Monitoring in Hospitals for Febrile Adverse Events in Patients with Cancer: A Prospective Feasibility Study

  2025cites this paper
• Preliminary efficacy and safety profile of dual histamine blockade on preventing filgrastim-associated bone pain in breast cancer patients: Randomized controlled trial.

  2025cites this paper
• Optimizing nursing care for neutropenic patients: a holistic perspective on education, support, and clinical management

  2025cites this paper
• Efficacy of Granulocyte Transfusions in Treating Neutropenic Infections: A Systematic Review and Meta-Analysis of Intervention Studies.

  2025cites this paper
• Complication Rates of Peripherally Inserted Central Catheters in Oncologic Versus Non-Oncologic Patients.

  2024cites this paper
• A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants

  2024cites this paper
• Impact of a Fast Pass on Emergency Department Wait Times for Oncology Patients with Febrile Neutropenia.

  2024cites this paper
• Assessing health outcomes: a systematic review of electronic patient-reported outcomes in oncology

  2024cites this paper
• Budget impact analysis of TPMT and NUDT15 pharmacogenomic testing for 6-mercaptopurine in pediatric acute lymphoblastic leukemia patients

  2024cites this paper
• Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pre-treatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor

  2024cites this paper
• Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US

  2024cites this paper
• Unveiling the Variances: Myelodysplastic Syndrome (MDS) Patient Admissions in Teaching vs Nonteaching Hospitals

  2024cites this paper
• Risk factors for resistant gram-positive bacteremia in febrile neutropenic patients with cancer.

  2024cites this paper
• The long-term impact of an antimicrobial stewardship program in febrile neutropenia: an 8 years follow up

  2024cites this paper
• Overcoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center

  2024cites this paper
• Economic implications of step-down outpatient management for fever and neutropenia episodes in pediatric cancer patients: a cost minimization analysis

  2024influential citation
• Fluoroquinolone Prophylaxis in Children with Cancer: A Pro/Con Discussion.

  2024cites this paper
• Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices

  2023cites this paper
• Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States

  2023cites this paper
• Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment

  2023cites this paper
• Falls prechemotherapy and toxicity‐related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial

  2023cites this paper
• Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer

  2023cites this paper
• The Yield, Safety, and Cost-effectiveness of Decreasing Repeat Blood Cultures Beyond 48 Hours in a Pediatric Hematology-Oncology Unit

  2023cites this paper
• Absolute Monocyte Count as Early and Safe Marker for Antibiotic Cessation in Febrile Neutropenia Without Etiology in Pediatric Oncology Patients

  2023cites this paper
• Personalized, connected health enabled by AI and home-based diagnostics.

  2023cites this paper
• The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps

  2023cites this paper
• Two decades of pegfilgrastim: what have we learned? Where do we go from here?

  2023cites this paper
• Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.

  2022cites this paper
• Cost-Effectiveness and Economic Burden Analyses on all First-Line Treatments of Chronic Lymphocytic Leukemia.

  2022cites this paper
• Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

  2022cites this paper
• Usability Evaluation of a Noninvasive Neutropenia Screening Device (PointCheck) for Patients Undergoing Cancer Chemotherapy: Mixed Methods Observational Study

  2022cites this paper
• Granulocyte Colony-Stimulating Factor Utilization and Prescribing Patterns in Cancer Patients: A Single Institution Experience of a Saudi Cancer Center

  2022cites this paper
• Decreased incidence of febrile neutropenia in Michigan following masking and social distancing orders for the COVID-19 pandemic: A population based cohort study

  2022cites this paper
• Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: A systematic review of randomised controlled trials.

  2022cites this paper
• Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit

  2022cites this paper
• Management of chemotherapy-induced febrile neutropenia and use of granulocyte colony-stimulating factor in patients with soft tissue or bone sarcoma

  2022cites this paper
• Outcomes in Patients With Curative Malignancies Receiving Filgrastim as Primary Prophylaxis.

  2022cites this paper
• Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type

  2022cites this paper
• Approach to fever in patients with neutropenia: a review of diagnosis and management

  2022cites this paper
• Resource Use and Costs Related to Hematological Complications of Chemotherapy: Cost of Illness Study Based on Data from Balkan Country with Recent History of Socioeconomic Transition

  2022influential citation
• The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy

  2022cites this paper
• The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study

  2022cites this paper
• Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward

  2021cites this paper
• Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy

  2021cites this paper
• Central Nervous System Infections in the Immunocompromised Adult Presenting to the Emergency Department.

  2021cites this paper
• Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

  2021cites this paper
• Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients

  2021cites this paper
• Quality of life of patients with leukemia undergoing chemotherapy

  2021cites this paper
• Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment

  2021cites this paper
• Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

  2021influential citation
• Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework

  2021cites this paper
• Association of Beta-Lactam Allergy Documentation and Antibiotic Use in Patients with Febrile Neutropenia.

  2021cites this paper
• Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety

  2021cites this paper
• Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity

  2021cites this paper
• Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

  2021cites this paper
• Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART)

  2021cites this paper
• A Novel Wearable Device for Continuous Temperature Monitoring & Fever Detection

  2021cites this paper
• Management Costs of Febrile Neutropenia in Oncology Patients in Colombia

  2021cites this paper
• Awareness of the risk of radiation-related caries in patients with head and neck cancer: A survey of physicians, dentists, and patients.

  2021cites this paper
• Pegfilgrastim Biosimilars: Where Are We Now?

  2021influential citation
• Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART)

  2021cites this paper
• Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients

  2021cites this paper
• Usefulness analysis of the 2018 ASCO/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy

  2021cites this paper
• Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment

  2021influential citation
• Remote Monitoring of Patients With Hematologic Malignancies at High Risk of Febrile Neutropenia: Exploratory Study

  2021cites this paper
• Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy

  2021cites this paper
• Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers

  2021cites this paper
• Decreased Incidence of Michigan Emergency Department Visits for Febrile Neutropenia Observed After Public Health Measures for the COVID-19 Pandemic

  2021cites this paper
• Optimizing Empiric Vancomycin Use in Febrile Neutropenia Patients

  2021cites this paper
• CEOR_A_302682 465..473

  2021cites this paper
• Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

  2021cites this paper
• Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy

  2020cites this paper
• Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer

  2020cites this paper
• Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

  2020cites this paper
• Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia

  2020cites this paper
• Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma

  2020cites this paper
• ABRANGÊNCIA DA ODONTOLOGIA HOSPITALAR: REVISÃO DE LITERATURA

  2020cites this paper
• Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv

  2020cites this paper
• Cost‐effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective

  2020cites this paper
• Infectious disease considerations in immunocompromised patients.

  2020cites this paper
• A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®)

  2020cites this paper
• The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients

  2020cites this paper
• Uso del Hebervital en Oncopediatría del Instituto Nacional de Oncología y Radiobiología, 2006-2016

  2020cites this paper
• Impact of cardiovascular comorbidities on inpatient mortality in patients hospitalized with neutropenic fever

  2020cites this paper
• Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer

  2020cites this paper
• Visualization of blood cell contrast in nailfold capillaries with high-speed reverse lens mobile phone microscopy.

  2020cites this paper
• Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in Italy.

  2020cites this paper